Table 3.
Number of patients experiencing treatment failure by days.
| Day(s) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | 7 | 13 | 14 | 16 | 18 | 19 | 20 | 21 | 22 | 23 | 26 | 28 |
| Artequick (1) | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Artequick (2)b | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 1 |
| ASMQ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Artequick (3)a | 0 | 1 | 5 | 1 | 1 | 1 | 2 | 0 | 1 | 2 | 2 | 1 |
| Artequick (4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Artekin | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coartem | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
One case of minimal antimalarial effect (RIII)
One case of early recrudescence (RII)